open access

Vol 16, No 1 (2020)
Case report
Published online: 2020-02-28
Get Citation

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)

Róża Poźniak-Balicka, Dawid Murawa
DOI: 10.5603/OCP.2020.0007
·
Oncol Clin Pract 2020;16(1):36-39.

open access

Vol 16, No 1 (2020)
CASE REPORT
Published online: 2020-02-28

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has recently been recognised, and so far approximately 200 cases have been described worldwide. From a histopathological and molecular perspective, it does not differ from classical breast anaplastic large cell lymphoma without ALK kinase expression. However, it has a different clinical course and prognosis, with a five-year survival rate about 92% as compared to 20–50% in patients with the classic form. A 60-year-old female patient had undergone bilateral mastectomy at the age of 45 years due to fibrocystic mastopathy and frequent breast cancer in her family history. Her implants were changed twice due to rupture. In 2018 the patient noticed a growing swelling of the right breast and fluid accumulation in the implant pouch; in September 2018 both implants were removed together, with the pouch also thoroughly removed during the procedure, and other PolyTech implants were inserted. Histological examination revealed the following: breast implant-associated anaplastic large cell lymphoma, immunophenotype: CD30+, ALK–, CD68, PGM–, CKAE1/AE3–, Ki 67 in 90% of cell nuclei. The patient was in very good general condition and without abnormalities in haematological tests. In PET-CT with 18F-FDG (13/12/2018), areas of slightly increased 18F-FDG activity were found in the vicinity of the implants on the right side (SUV max = 1.9) and on the left side (SUV max = 2.3), in addition to left axillary lymph node 12 × 7 × 8 mm (SUV max = 2.0). The patient did not decide to go ahead with the proposed removal of the implants, and a suspicious node was taken for examination — no cancer architecture was found. A control PET-CT test was performed after four months, the result of which was comparable to the previous one. The patient is under observation.

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has recently been recognised, and so far approximately 200 cases have been described worldwide. From a histopathological and molecular perspective, it does not differ from classical breast anaplastic large cell lymphoma without ALK kinase expression. However, it has a different clinical course and prognosis, with a five-year survival rate about 92% as compared to 20–50% in patients with the classic form. A 60-year-old female patient had undergone bilateral mastectomy at the age of 45 years due to fibrocystic mastopathy and frequent breast cancer in her family history. Her implants were changed twice due to rupture. In 2018 the patient noticed a growing swelling of the right breast and fluid accumulation in the implant pouch; in September 2018 both implants were removed together, with the pouch also thoroughly removed during the procedure, and other PolyTech implants were inserted. Histological examination revealed the following: breast implant-associated anaplastic large cell lymphoma, immunophenotype: CD30+, ALK–, CD68, PGM–, CKAE1/AE3–, Ki 67 in 90% of cell nuclei. The patient was in very good general condition and without abnormalities in haematological tests. In PET-CT with 18F-FDG (13/12/2018), areas of slightly increased 18F-FDG activity were found in the vicinity of the implants on the right side (SUV max = 1.9) and on the left side (SUV max = 2.3), in addition to left axillary lymph node 12 × 7 × 8 mm (SUV max = 2.0). The patient did not decide to go ahead with the proposed removal of the implants, and a suspicious node was taken for examination — no cancer architecture was found. A control PET-CT test was performed after four months, the result of which was comparable to the previous one. The patient is under observation.

Get Citation

Keywords

anaplastic breast lymphoma, breast implant, textured implant

About this article
Title

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 1 (2020)

Article type

Case report

Pages

36-39

Published online

2020-02-28

DOI

10.5603/OCP.2020.0007

Bibliographic record

Oncol Clin Pract 2020;16(1):36-39.

Keywords

anaplastic breast lymphoma
breast implant
textured implant

Authors

Róża Poźniak-Balicka
Dawid Murawa

References (16)
  1. Miszczyk JM, Charytonowicz M, Charytonowicz D. Guzek, obrzęk, deformacja piersi — problem dla hematologa? Onkologia po Dyplomie. 2016; 05.
  2. Keech JA, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 1997; 100(2): 554–555.
  3. Center for Devices and Radiological Health, U.S. Food and Drug Administra- tion. Anaplastic large cell lymphoma (ALCL) in women with breast implants: preliminary FDA ndings and analysis. FDA (online) 2011; http://www.fda. gov/downloads/MedicalDevices/ProductsandMedicalProcedures/Implant- sandProsthetics/BreastImplants/UCM240003.pdf.
  4. Talwalkar SS, Miranda RN, Valbuena JR, et al. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol. 2008; 32(9): 1299–1309.
  5. Validire P, Capovilla M, Asselain B, et al. Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol. 2009; 84(3): 133–139.
  6. Gualco G, Chioato L, Harrington WJ, et al. Primary and secondary T-cell lymphomas of the breast: clinico-pathologic features of 11 cases. Appl Immunohistochem Mol Morphol. 2009; 17(4): 301–306.
  7. Bizjak M, Selmi C, Praprotnik S, et al. Silicone implants and lymphoma: The role of inflammation. J Autoimmun. 2015; 65: 64–73.
  8. Miszczyk J, Charytonowicz M. Anaplastyczny chłoniak wielkokomórkowy związany z implantami piersi (BI A-ALCL ) — podsumowanie aktualnego stanu wiedzy. Chirurgia Plastyczna i Oparzenia. 2015; 3(4): 169–172.
  9. Eaves F, Nahai F. Anaplastic large cell lymphoma and breast implants: FDA report. Aesthet Surg J. 2011; 31(4): 467–468.
  10. Jacombs A, Tahir S, Hu H, et al. In vitro and in vivo investigation of the influence of implant surface on the formation of bacterial biofilm in mammary implants. Plast Reconstr Surg. 2014; 133(4): 471e–80e.
  11. Brody GS, Deapen D, Taylor CR, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015; 135(3): 695–705.
  12. Jewell M, Spear SL, Largent J, et al. Anaplastic large T-cell lymphoma and breast implants: a review of the literature. Plast Reconstr Surg. 2011; 128(3): 651–661.
  13. Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014; 32(2): 114–120.
  14. Xu J, Wei S. Breast implant-associated anaplastic large cell lymphoma: review of a distinct clinicopathologic entity. Arch Pathol Lab Med. 2014; 138(6): 842–846.
  15. Carty MJ, Pribaz JJ, Antin JH, et al. A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg. 2011; 128(3): 112e–118e.
  16. Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016; 34(2): 160–168.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl